<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796874</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000618738</org_study_id>
    <secondary_id>RPCI-I-124107</secondary_id>
    <nct_id>NCT00796874</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance</brief_title>
  <official_title>MR Imaging to Stratify Prostate Cancer Progression Risk in Patients on Active Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sometimes prostate cancer may not need treatment until it progresses. In this&#xD;
      case, active surveillance may be sufficient. Diagnostic procedures, such as magnetic&#xD;
      resonance imaging, may be a less invasive method of finding prostate cancer that has&#xD;
      progressed.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well magnetic resonance imaging works in&#xD;
      detecting cancer progression in patients with early-stage prostate cancer who are undergoing&#xD;
      active surveillance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine if MRI parameters (initial volume, number and location of image&#xD;
           abnormalities, and MR spectroscopy) can improve the ability to stratify cancer&#xD;
           progression risk in patients undergoing active surveillance for early-stage prostate&#xD;
           cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine if changes in non-invasive MRI, validated by MRI-guided biopsies, can&#xD;
           accurately detect progression of prostate cancer.&#xD;
&#xD;
      OUTLINE: Patients undergo prostate MRI scans and MRI-guided biopsies of suspicious lesions at&#xD;
      baseline. Patients undergo conventional anatomic imaging followed by research biological&#xD;
      imaging tests (e.g., magnetic resonance spectroscopic imaging and/or dynamic&#xD;
      contrast-enhanced MRI). MRI are repeated at 6 months, 1 year, and then annually until&#xD;
      initiation of definitive therapy or for a total of 5 years.&#xD;
&#xD;
      Tissue biopsy with MRI guidance is done at baseline and annually or as clinically indicated&#xD;
      based on change in rectal exam, PSA, or maybe done based on change in MR imaging (i.e., new&#xD;
      MR lesion or significant change [&gt; 25% increase] in the size of a MR lesion).&#xD;
&#xD;
      Blood samples are collected at baseline and periodically during study for PSA tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI decided to terminate study.&#xD;
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate cancer progression measured by MRI while on active surveillance</measure>
    <time_frame>at 6 months, 1 year and than annualy for 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer changes by MRI</measure>
    <time_frame>At 6months, 1 year and annually for 5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>active surveillance</intervention_name>
    <description>Correlative Study</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>imaging biomarker analysis</intervention_name>
    <description>Correlative Study</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Tissue Removal</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dynamic contrast-enhanced magnetic resonance imaging</intervention_name>
    <description>Radiolical Medical Imaging</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
    <description>Radiolical Medical Imaging</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance spectroscopic imaging</intervention_name>
    <description>Radiolical Medical Imaging</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed prostate cancer&#xD;
&#xD;
          -  Low-risk for progression, as evidenced by all of the following:&#xD;
&#xD;
               -  Tumor stage ≤ T2a&#xD;
&#xD;
               -  PSA ≤ 10 ng/mL&#xD;
&#xD;
               -  Gleason score ≤ 7&#xD;
&#xD;
          -  Patients informed of treatment options and has already chosen to undergo active&#xD;
             surveillance&#xD;
&#xD;
               -  No decision to stop active surveillance&#xD;
&#xD;
          -  No node-positive or metastatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Willing to undergo MRI&#xD;
&#xD;
          -  Willing to undergo prostate biopsy&#xD;
&#xD;
          -  No contraindications to MRI that include, but not limited to, any of the following:&#xD;
&#xD;
               -  Claustrophobia&#xD;
&#xD;
               -  Anxiety&#xD;
&#xD;
               -  Presence of metal or shrapnel in the body&#xD;
&#xD;
               -  Pacemakers&#xD;
&#xD;
               -  Old tattoos with metal-based dye material&#xD;
&#xD;
          -  No contraindication to prostate biopsy&#xD;
&#xD;
          -  No medical conditions, as deemed by the PI or associates, that would prevent or limit&#xD;
             the patient participation on the protocol that include, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Severe coagulopathy&#xD;
&#xD;
               -  History of severe bleeding&#xD;
&#xD;
               -  Severe coronary artery disease&#xD;
&#xD;
               -  Other comorbid conditions that limit life expectancy to less than 2 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No hormone therapy within the past year&#xD;
&#xD;
          -  No prior pelvic radiotherapy&#xD;
&#xD;
          -  No prior prostate resection including transurethral resection of prostate&#xD;
&#xD;
          -  Concurrent participation in other clinical studies (e.g., vitamin D, selenium) allowed&#xD;
             provided active surveillance is continued&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anurag K. Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>November 21, 2008</study_first_submitted>
  <study_first_submitted_qc>November 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2008</study_first_posted>
  <last_update_submitted>July 24, 2013</last_update_submitted>
  <last_update_submitted_qc>July 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

